Citations

Showing 10 of 108094 citations.

Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections
Durko, Andras P. , Osnabrugge, Ruben L.J. , Milojevic, Milan , Mylotte, Darren , Milojevic, Milan , Mieghem, Nicolas M. Van , Nkomo, Vuyisile T. , Kappetein, A. Pieter , Milojevic, Milan

Mayo Clinic

European Heart Journal | February 19, 2018 | Volume: 39 | Issue: 28 | Pages: 2635-2642

10.1093/eurheartj/ehy107 | PMID 29546396 Get It

When Do α-Synucleinopathies Start? An Epidemiological Timeline
Savica, Rodolfo , Mielke, Michelle M. , Mielke, Michelle M , Boeve, Bradley F.

Mayo Clinic

JAMA Neurology | February 19, 2018 | Volume: 75 | Issue: 4 | Pages: 503

10.1001/jamaneurol.2017.4243 | PMID 29459985 Get It

Machine Learning as a Potential Solution for Shift During Stereotactic Brain Surgery
Abi-Aad, Karl R., Anderies, Barrett J. , Welz, Matthew E., Bendok, Bernard R.

Mayo Clinic

Neurosurgery | February 19, 2018 | Volume: 82 | Issue: 5 | Pages: E102-E103

10.1093/neuros/nyy043 | PMID 29669121 Get It

Investigating Speech Recognition and listening effort with different device configurations in adult cochlear implant users
Sladen, Douglas P. , Nie, Yingjiu , Berg, Katelyn A.

Mayo Clinic

Cochlear Implants International | February 19, 2018 | Volume: 19 | Issue: 3 | Pages: 119-130

10.1080/14670100.2018.1424513 | PMID 29457564 Get It

An International Multispecialty Validation Study of the IgG4‐Related Disease Responder Index
Wallace, Zachary S. , Khosroshahi, Arezou , Carruthers, Mollie D., Perugino, Cory A. , Campochiaro, Corrado , Culver, Emma , Cortazar, Frank B. , Ebbo, Mikaël , Fernandes, Ana D. , Frulloni, Luca , Hart, Phil A. , Karadağ, Ömer , Kawa, Shigeyuki , Kim, Myung‐Hwan , Lanzillotta, Marco , Matsui, Shoko , Okazaki, Kazuichi , Ryu, Jay H. , Saeki, Takako , Schleinitz, N. , Tanasa, Paula, Umehara, Hisanori , Webster, George, Stone, John H. , Ryu, Jay H , Carruthers, Mollie D., Choi, Hyon K. , Della‐Torre, Emanuel , Kawano, Mitsuhiro , Zhang, Wen , Campochiaro, Corrado

Mayo Clinic

Arthritis Care & Research | February 18, 2018 | Volume: 70 | Issue: 11 | Pages: 1671-1678

10.1002/acr.23543 | PMID 29457382 Get It

ObjectiveIgG4‐related disease (IgG4‐RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4‐RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation.MethodsThe RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4‐RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness.ResultsThe 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P < 0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P < 0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively.DiscussionIn this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy.
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Shrader, Peter, Pieper, Karen S. , Thomas, Laine , Ansell, Jack , Ezekowitz, Michael D. , Kowey, Peter R. , Reiffel, James A. , Singer, Daniel E. , Piccini, Jonathan P. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) II, Barrett, Tyler W. , Gazmuri, Raúl J. , Steinberg, Benjamin A. , Allen, Larry A. , Chan, Paul S. , Fonarow, Gregg C. , Freeman, James V. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Naccarelli, Gerald V. , Peterson, Eric D. , Investigators, the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) II, Gazmuri, Raúl J

Mayo Clinic

Journal of the American Heart Association | February 17, 2018 | Volume: 7 | Issue: 4 | Pages: No page available

10.1161/jaha.117.007633 | PMID 29453305 Get It

Background Non–vitamin K antagonist oral anticoagulants (NOACs) are indicated for stroke prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to describe the frequency, appropriateness (according to Food and Drug Administration labeling), and outcomes of patients prescribed reduced doses of NOACs in community practice. Methods and Results We analyzed data from the ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II) registry, a prospective, national, observational registry of AF patients. Among 7925 AF patients receiving NOACs, we assessed patterns of use of reduced NOAC doses and associated cardiovascular and bleeding outcomes at median follow‐up of 1 year. Overall, 6636 patients (84%) received a NOAC at standard dose, which was consistent with US Food and Drug Administration labeling in 6376 (96%). Reduced NOAC dose was prescribed to 1289 (16% overall), which was consistent with Food and Drug Administration labeling in only 555 patients (43%). Compared with those whose NOAC dose was appropriately reduced, patients receiving inappropriate dose reductions were younger (median age 79 versus 84, P <0.0001) and had lower ORBIT bleeding risk scores (26% ≥4 versus 45%, P <0.0001). Compared with those appropriately receiving standard dosing, patients receiving inappropriately reduced‐dose NOACs had higher unadjusted rates of thromboembolic events (2.11 versus 1.35 events per 100 patient years, hazard ratio 1.56, 95% confidence interval 0.92‐2.67) and death (6.77 versus 2.60, hazard ratio 2.61, 95% confidence interval 1.86‐3.67). After adjustment, outcomes were not significantly different but tended to favor patients dosed appropriately. Conclusions The majority of dose reductions of NOACs in AF are inconsistent with US Food and Drug Administration recommendations. There appear to be opportunities to improve current NOAC dosing in community practice. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure
Sangaralingham, Lindsey R. , Sangaralingham, S. Jeson , Shah, Nilay D., Yao, Xiaoxi , Dunlay, Shannon M. , Sangaralingham, S. Jeson

Mayo Clinic

Circulation: Heart Failure | February 17, 2018 | Volume: 11 | Issue: 2 | Pages: No page available

10.1161/circheartfailure.117.004302 | PMID 29453287 Get It

Background: The US Food and Drug Administration approved the use of sacubitril/valsartan in patients with heart failure with reduced ejection fraction in July 2015. We aimed to assess the adoption and prescription drug costs of sacubitril/valsartan in its first 18 months after Food and Drug Administration approval. Methods and Results: Using a large US insurance database, we identified privately insured and Medicare Advantage beneficiaries who filled a first prescription for sacubitril/valsartan between July 1, 2015, and December 31, 2016. We compared them to patients treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Outcomes included adoption, prescription drug costs, and 180-day adherence, defined as a proportion of days covered ≥80%. A total of 2244 patients initiated sacubitril/valsartan. Although the number of users increased over time, the proportion of heart failure with reduced ejection fraction patients taking sacubitril/valsartan remained low (<3%). Patients prescribed sacubitril/valsartan were younger, more often male, with less comorbidity than those taking an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Although a majority of prescription costs were covered by the health plan (mean, $328.37; median, $362.44 per 30-day prescription), out-of-pocket costs were still high (mean, $71.16; median, $40.27). By comparison, median out-of-pocket costs were $2 to $3 for lisinopril, losartan, carvedilol, and spironolactone. Overall, 59.1% of patients were adherent to sacubitril/valsartan. Refill patterns suggested that nearly half of nonadherent patients discontinued sacubitril/valsartan within 180 days of starting. Conclusions: Adoption of sacubitril/valsartan after Food and Drug Administration approval has been slow and may be associated with the high cost.
Variability in asthma quality and costs in children with different Medicaid insurance plans in Maricopa County
Rank, Matthew A. , Landman, Natalie, Harootunian, Gevork, Winscott, Michelle, Jain, Neil , Frey, Keith A. , Wilson, Gena, Drewek, Rupali , Parra-Roide, Lilia, Wilson, Charlton, Smoldt, Robert K., Cortese, Denis A., Rank, Matthew

Mayo Clinic

Journal of Asthma | February 16, 2018 | Volume: 56 | Issue: 2 | Pages: 152-159

10.1080/02770903.2018.1432644 | PMID 29451814 Get It

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
Wang, Yugang , Henderson, James , Niknafs, Yashar S., Qiao, Yuanyuan , Gursky, Amy, Chung, Jae‐Seung , Smith, David C. , Karnes, R. Jeffrey , Feng, Felix Y. , Palapattu, Ganesh S. , Tomlins, Scott A. , Morgan, Todd M. , Morgan, Todd M , Singhal, Udit , Zaslavsky, Alexander , Chang, S. Laura , Taichman, Russell S. , Chinnaiyan, Arul

Mayo Clinic

Molecular Cancer Research | February 16, 2018 | Volume: 16 | Issue: 4 | Pages: 643-654

10.1158/1541-7786.mcr-17-0539 | PMID 29453313 Get It

Abstract The trend toward precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration-resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer–related genes. CTCs were isolated from the whole blood of mCRPC patients (n = 41) and multiplex qPCR was performed to evaluate expression of prostate cancer–related target genes (n = 78). A large fraction of patients (27/41, 66%) had detectable CTCs. Increased androgen receptor (AR) expression (70% of samples) and evidence of Wnt signaling (67% of samples) were observed. The TMPRSS2:ERG fusion was expressed in 41% of samples, and the aggressive prostate cancer–associated long noncoding RNA SChLAP1 was upregulated in 70%. WNT5a [HR 3.62, 95% confidence interval (CI), 1.63–8.05, P = 0.002], AURKA (HR 5.56, 95% CI, 1.79–17.20, P = 0.003), and BMP7 (HR 3.86, 95% CI, 1.60–9.32, P = 0.003) were independently predictive of overall survival (FDR &lt; 10%) after adjusting for a panel of previously established prognostic variables in mCRPC (Halabi nomogram). A model including Halabi, WNT5a, and AURKA expression, termed the miCTC score, outperformed the Halabi nomogram alone (AUC = 0.89 vs. AUC = 0.70). Understanding the molecular landscape of CTCs has utility in predicting clinical outcomes in patients with aggressive prostate cancer and provides an additional tool in the arsenal of precision-based therapeutic approaches in oncology. Implications: Analysis of CTC gene expression reveals a clinically prognostic “liquid biopsy” signature in patients with metastatic castrate-resistance prostate cancer. Mol Cancer Res; 16(4); 643–54. ©2018 AACR.